What is the function of Milrinone (Primacor) in heart failure therapy?

Milrinone (Primacor) serves a specific role in the management of heart failure, particularly as a short-term intravenous therapy aimed at increasing cardiac output. This medication belongs to a class of drugs known as phosphodiesterase inhibitors, which enhance the contractility of the heart muscle. By doing so, Milrinone helps improve the heart's ability to pump blood more effectively, which is particularly valuable in acute heart failure settings where patients may experience significant hemodynamic instability.

Using Milrinone intravenously allows for rapid effects, making it suitable for patients who require immediate support to augment cardiac function. This is particularly useful in clinical scenarios such as decompensated heart failure, where patients may need quick stabilization while other long-term treatments are being arranged.

The other options present various concepts not related to the primary function of Milrinone. Long-term oral therapy does not apply to Milrinone since it is typically administered intravenously for short-term support. While diuretics are essential in managing fluid overload in heart failure, they do not describe Milrinone's mechanism. Lastly, vasoconstriction is contrary to the therapeutic effect of Milrinone, as it actually has vasodilatory effects, helping to reduce the overall workload on the heart